[Policy Review] Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada

The clinical development of cancer therapeutics is a global undertaking, and incorporation of the patient experience into the clinical decision-making process is of increasing interest to the international regulatory and health policy community. Disease and treatment-related symptoms and their effect on patient function and health-related quality of life are important outcomes to consider. The identification of methods to scientifically assess, analyse, interpret, and present these clinical outcomes requires sustained international collaboration by multiple stakeholders including patients, clinicians, scientists, and policy makers.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Policy Review Source Type: research